The non-peptidic HIV protease inhibitor tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate Pneumocystis carinii growth and proteasome activity of HEL299 cell line

Journal of Eukaryotic Microbiology

Volumn 53, Issue SUPPL. 1, 2006, Pages

  Mazza, Francesca ^a   Tronconi, Elisa ^a   Valerio, Antonella ^a   Groettrup, Marcus ^b   Kremer, Marcel ^b   Tossi, Alessandro ^c   Benedetti, Fabio ^c   Cargnel, Antonietta ^a   Atzori, Chiara ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; COUMARIN DERIVATIVE; N SUCCINYL LEUCYL LEUCYL VALYL TYROSYL 7 AMINO 4 METHYLCOUMARIN; N-SUCCINYL-LEUCYL-LEUCYL-VALYL-TYROSYL-7-AMINO-4-METHYLCOUMARIN; OLIGOPEPTIDE; PROTEASOME; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE; TIPRANAVIR;

FUNGUS; GROWTH RATE; HUMAN IMMUNODEFICIENCY VIRUS;

ANIMAL; CELL LINE; CONFERENCE PAPER; DRUG ANTAGONISM; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; PNEUMOCYSTIS CARINII; RAT;

ANIMALS; ANTIFUNGAL AGENTS; CELL LINE; COUMARINS; HIV PROTEASE INHIBITORS; HUMANS; OLIGOPEPTIDES; PNEUMOCYSTIS CARINII; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRIDINES; PYRONES; RATS;

HUMAN IMMUNODEFICIENCY VIRUS; PNEUMOCYSTIS CARINII;

EID: 33751372132     PISSN: 10665234     EISSN: 15507408     Source Type: Journal    
DOI: 10.1111/j.1550-7408.2006.00208.x     Document Type: Conference Paper

References (10)

1. Atzori, C., Angeli, E., Mainini, A., Agostoni, F., Micheli, V. & Cargnel, A. 2000. In vitro activity of human immunodeficiency virus protease inihibitors against Pneumocystis carinii. J. Infect. Dis., 181:1629-1634.
2. Atzori, C., Fantoni, G., Valerio, A. & Cargnel, A. 2001. In vitro activity of amprenavir against Pneumocystis carinii. Int. J. Antimicrob. Agents, 18:271-273.
3. Groettrup, M., Ruppert, T., Kuehn, L., Seeger, M., Standera, S., Koszinowski, U. & Kloetzel, P. M. 1995. The interferon-γ-inducible 11S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro. J. Biol. Chem., 270:23808-23815.
4. Mazza, F. 2002-2003. Study of the effect of the HIV protease inhibitors lopinavir and atazanavir on in vitro Pneumocystis Carinii growth. Dissertation, University of Milano-Bicocca, Milan, Italy, 78 p.
5. Piccinini, M., Mostert, M. & Rinaudo, M. T. 2003. Proteasomes as drug targets. Cur. Drug Targets, 4:657-671.
6. Ripka, A. S. & Rich, D. H. 1998. Peptidomimetic design. Cur. Opin. Chem. Biol., 2:441-452.
7. Sepkowitz, K. A. 1998. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet, 351:228-230.
8. Schmidtke, G., Emch, S., Groettrup, M. & Holzhutter, H. G. 2000. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20S proteasome. J. Biol. Chem., 275:22056-22063.
9. Tossi, A., Benedetti, F., Norbedo, S., Skrbec, D., Berti, F. & Romeo, D. 2003. Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases. Bioorg. Med. Chem., 11:4719-4727.
10. Waring, J., Ciurlionis, R., Marsh, K., Klein, L., Degoey, D., Randolph, J., Spear, B. & Kempf, D. 2005. Identification of proteasome gene regulation in rat model for HIV-induced hyperlipidemia using microarray analysis. Abstract 839. Conference on Retroviruses and Opportunistic Infections.